Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01489644 · ClinicalTrials.gov registry record · Phase 1

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers

A Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 1
Development phase
62
Enrollment target
2
Study locations

NCT01489644: Completed Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.

NCT01489644 is a Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 62 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01489644, a Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 1
Development phase
62 participants
Enrollment target
2
Study locations

Study Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to compare repaglinide and metformin administered as an individual tablets with repaglinide and metformin administered as a combination tablet.

Interventions

  • DRUG metformin
  • DRUG repaglinide
  • DRUG repaglinide and metformin combination tablet

Study Locations (2)

Florida

  • Novo Nordisk Investigational Site - Miami

Washington

  • Novo Nordisk Investigational Site - Tacoma

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2006-06
Est. Completion 2006-07
Phase Phase 1
Novo Nordisk A/S

431 total trials

What the finished NCT01489644 record still lists

NCT01489644 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which metformin is the first listed.

NCT01489644 reports a single indexed study location in Florida, Washington.

Frequently Asked Questions

What is clinical trial NCT01489644 about?

NCT01489644 is a clinical study titled "Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers". This trial is conducted in the United States of America (USA). The aim of this trial is to compare repaglinide and metformin administered as an individual tablets with repaglinide and metformin administered as a combination tablet.

What is the current status of trial NCT01489644?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2006-06. Estimated completion is 2006-07.

What conditions does trial NCT01489644 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes.

What interventions are being tested in trial NCT01489644?

The interventions under investigation include: metformin (DRUG), repaglinide (DRUG), repaglinide and metformin combination tablet (DRUG).

Who is sponsoring clinical trial NCT01489644?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01489644 being conducted?

This trial has 2 study locations across Florida, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01489644's enrollment target sits among peer trials

62 240th of 348 higher than 106 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01489644, the US trial registry maintained by the National Library of Medicine. NCT01489644 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.